Alnylam Maintains 2030 25% CAGR Despite 2026 Guidance Reset, H2 Focus

Impact of updated 2026 guidance on the 12–24 month outlook and the 25% CAGR through 2030

1) What changed in 2026 guidance—and why it matters for H2

Alnylam revised its full-year 2026 guidance for total net product revenue to $4.7B–$5.1B, with the midpoint at $4.9B. ¹ Management attributed the reduction at the midpoint (vs. original TTR guidance) to a better understanding of how second-line demand normalizes as the launch progresses. ²

The company also said the midpoint 2026 revenue implies that, in H2 2026, growth would need to be consistent with Q2 2026 (i.e., the “same kind of growth run-rate” rather than letting a bigger step-down occur). ³ Management’s math/expectation from the question being addressed was that under the new guide Alnylam would be growing ~50% at the midpoint in the second half of 2026. ⁴

Key implication for the next 12–24 months: even though full-year guidance is lowered, the revised midpoint still requires strong H2 performance, which reduces the likelihood of a sharp near-term growth collapse. ³⁴

2) How this affects the 12–24 month outlook (H2 2026 into 2027)

Near-term optics: weaker full-year “trajectory,” but not a weaker H2 growth requirement

• The guidance change reflects second-line normalization (a “drop-off” they didn’t model correctly initially). ²
• However, management explicitly framed revised guidance as requiring Q3 and Q4 growth consistent with Q2 to reach the revised midpoint. ³

So the updated guidance affects the outlook more as a reallocation within growth drivers (less “catch-up” from early second-line pent-up demand; more contribution expected from first-line momentum) than as a broad-based demand deterioration. ²¹

1st-line momentum is positioned as the stabilizer for 12–24 months

Management emphasized that first-line demand is the primary focus and is the driver they believe can sustain the longer-term growth plan. ¹ They also described a market structure where 80% of patients remain untreated, and that within ~15 months they built a “very strong base,” with first-line rapidly replacing what was initially stronger in second-line as the launch matured. ⁵

Additionally, they said that early second-line volume growth had been influenced by pent-up demand from patients waiting for a new option, and that second-line volume growth moderated in early 2026 to a normalized level—which is the proximate reason for the $200M TTR guidance reduction. ²

Translation into a 12–24 month outlook: the company is effectively signaling that:

• Second-line growth will not stay at the initial “pent-up demand” elevated rate (that’s the normalization baked into the 2026 reset). ²
• First-line growth becomes relatively more important going forward, supported by continued prescriber expansion and adoption. ⁵⁶

Confidence statement is explicitly about maintaining the ramp needed to hit 2030

The management response directly addressed the concern about confidence to keep growth “likely above” the 25% CAGR for a while, referencing that revised 2030 goals are still intact. ⁴ They stated confidence in the near term (including H2 2026) based on strength in first-line demand in the U.S. and the ability to deliver the run-rate implied by the revised TTR. ³

3) Does stronger H2 growth midpoint undermine the “lower guidance” story—or support the 25% CAGR plan?

It actually supports the 25% CAGR story, in the company’s framing, because the lowered guidance is explained as a timing/normalization issue in second-line, not a denial of the broader demand opportunity. ²⁷

• The revisions lower expectations for TTR by $200M at the midpoint, but management still described robust 75% growth year-over-year for the revised TTR range $4.2B–$4.5B. ¹
• They also highlighted that the H2 run-rate must match Q2 levels to reach the revised midpoint, which implies they expect growth to remain strong through at least H2 2026. ³
• For 2030, management reiterated that they “still guided” to the 25% CAGR. ⁴ They further stated confidence in reaching 2030 goals based on strong fundamentals, particularly market growth and first-line momentum. ⁷⁵

4) What it means for the long-term goal of 25% CAGR through 2030

The long-term target is reaffirmed, with near-term adjustments framed as launch learning

Management acknowledged: “we’re not pleased to be lowering guidance,” but emphasized continued confidence that the fundamentals driving the opportunity remain strong, including market growth and first-line momentum. ⁷

They also directly connected their ability to demonstrate 25% CAGR growth year-over-year to:

• an untapped market (80% untreated), ⁵
• rapid early base-building, ⁵
• first-line rapidly replacing second-line as the launch progresses, ⁵
• and ongoing efforts to expand prescriber bases. ⁵⁶

So the guidance reset does not change the long-term “math target”; it changes the expected path (less pent-up second-line tail in the near term, more durability from first-line). ²⁵

Competitive/de-risking developments are cited as reinforcing the outlook

They referenced increased confidence in the future outlook based on developments such as the CARDIO-TRRansform study results and the associated competitive landscape. ⁸ They also reinforced the broader opportunity with data points like an estimate of ~200,000 patients and ~80% remaining untreated, and claimed ~40% year-over-year category growth with a single option, which management says has accelerated since launch. ⁹

While these are not financial-model statements in the excerpt, they are management’s asserted support for the demand environment underlying a 25% CAGR plan. ⁹⁷

5) Bottom line: how the updated 2026 guidance affects the 12–24 month outlook and the 2030 CAGR

• 12–24 month outlook: The revised guidance implies strong H2 2026 growth is still required (consistent with Q2), even though the full-year numbers are lowered because second-line demand is normalizing. ³² The company’s narrative is that the “drop-off” is largely about the mix/timing of second-line growth, not about an overall demand collapse. ²¹⁰
• 25% CAGR through 2030: The company reaffirmed the 25% CAGR target and argues that first-line momentum in a largely untreated market (80% untreated) plus continued prescriber expansion makes the long-term goal “within reach.” ⁴⁵⁷

In short, the updated 2026 guidance reshapes the near-term growth composition (less second-line pent-up contribution; more reliance on first-line durability) while still requiring strong near-term execution in H2—and management believes that path is consistent with sustaining the 2030 25% CAGR target. ²³⁵⁴